NasdaqGM - Delayed Quote USD

Axsome Therapeutics, Inc. (AXSM)

71.71 +0.19 (+0.27%)
At close: April 26 at 4:00 PM EDT
72.25 +0.54 (+0.75%)
After hours: April 26 at 6:48 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
270,600.00
270,600.00
50,037.00
--
--
Cost of Revenue
26,065.00
26,065.00
5,198.00
--
--
Gross Profit
244,535.00
244,535.00
44,839.00
--
--
Operating Expense
427,442.00
427,442.00
221,340.00
124,707.00
99,087.75
Operating Income
-182,907.00
-182,907.00
-176,501.00
-124,707.00
-99,087.75
Net Non Operating Interest Income Expense
-6,453.00
-6,453.00
-7,335.00
-5,696.00
-2,565.84
Other Income Expense
-48,918.00
-48,918.00
-3,298.00
--
-1,247.01
Pretax Income
-238,278.00
-238,278.00
-187,134.00
-130,403.00
-102,900.60
Tax Provision
960.00
960.00
--
--
--
Net Income Common Stockholders
-239,238.00
-239,238.00
-187,134.00
-130,403.00
-102,900.60
Diluted NI Available to Com Stockholders
-239,238.00
-239,238.00
-187,134.00
-130,403.00
-102,900.60
Basic EPS
-5.27
-5.27
-4.60
-3.47
-2.77
Diluted EPS
-5.27
-5.27
-4.60
-3.47
-2.77
Basic Average Shares
45,425.21
45,425.21
40,655.94
37,618.60
37,206.93
Diluted Average Shares
45,425.21
45,425.21
40,655.94
37,618.60
37,206.93
Total Operating Income as Reported
-231,825.00
-231,825.00
-179,799.00
-124,707.00
-99,141.33
Total Expenses
453,507.00
453,507.00
226,538.00
124,707.00
99,087.75
Net Income from Continuing & Discontinued Operation
-239,238.00
-239,238.00
-187,134.00
-130,403.00
-102,900.60
Normalized Income
-200,592.78
-200,592.78
-183,836.00
-130,403.00
-101,653.59
Interest Expense
6,453.00
6,453.00
7,335.00
5,696.00
2,565.84
Net Interest Income
-6,453.00
-6,453.00
-7,335.00
-5,696.00
-2,565.84
EBIT
-231,825.00
-231,825.00
-179,799.00
-124,707.00
-100,334.76
EBITDA
-224,991.00
-224,991.00
-175,397.00
-124,631.00
-100,257.04
Reconciled Cost of Revenue
25,606.00
25,606.00
4,935.00
--
--
Reconciled Depreciation
6,834.00
6,834.00
4,402.00
76.00
77.72
Net Income from Continuing Operation Net Minority Interest
-239,238.00
-239,238.00
-187,134.00
-130,403.00
-102,900.60
Total Unusual Items Excluding Goodwill
-48,918.00
-48,918.00
-3,298.00
--
-1,247.01
Total Unusual Items
-48,918.00
-48,918.00
-3,298.00
--
-1,247.01
Normalized EBITDA
-176,073.00
-176,073.00
-172,099.00
-124,631.00
-99,010.03
Tax Rate for Calcs
0.00
0.00
--
--
--
Tax Effect of Unusual Items
-10,272.78
-10,272.78
--
--
--
12/31/2020 - 11/19/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TGTX TG Therapeutics, Inc.
13.47
-3.16%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
LXRX Lexicon Pharmaceuticals, Inc.
1.5800
+2.60%
 
ALT Altimmune, Inc.
7.26
+0.83%
 
AVXL Anavex Life Sciences Corp.
3.4400
+1.47%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
SAVA Cassava Sciences, Inc.
22.34
+2.81%
 
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
ANVS Annovis Bio, Inc.
18.01
+32.43%